Gilead Sciences EVP Sells $1312560.00 in Stock (GILD)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) rose 5.52% with the overall traded volume of 2.83 million shares up its average volume of 1.16 million.

As for a valuation, the company stands out based on average EPS growth over the past five years which was 28.90%. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $118.20 target price on the stock.in a research note on Thursday, October 22nd. For example, if a company forecasts future profitability, the estimated P/E will be lower than the current P/E. P/E is calculated by dividing the market price per share by the expected earnings per share, and also referred to as price-to-earnings. Third quarter total revenue increased 18 percent to $2,334 million compared to $1,982 million in the third quarter of 2014.

In other Gilead Sciences news, CEO John C. Martin sold 150,000 shares of the stock in a transaction dated Tuesday, September 1st. The company’s quarterly revenue was up 37.3% compared to the same quarter previous year. Following the sale, the chief executive officer now owns 3,948,066 shares of the company’s stock, valued at approximately $415,218,101.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Piper Jaffray restated a “buy” rating on shares of Gilead Sciences in a research report on Saturday, July 25th. Finally, Morgan Stanley upped their price target on Gilead Sciences to $123.00 in a research report on Wednesday, October 28th. The company has a 52-week high of $123.37. The rating is an average of the various different ratings given by analysts and brokers to Gilead Sciences Incorporated, and then averaged into one rating by a team of analysts at Zacks in Chicago, Illinois. The stock price is below the 200 days simple moving average. An excerpt of nineteen Wall Street equity analysts who have analysed Gilead Sciences Inc shows they expect it to earn $12.21 per share in 2015 for a price-earnings ratio of 8.54. Also, EVP Norbert W. Bischofberger sold 70,000 shares of the stock in a transaction dated Monday, August 17th.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Wednesday, December 16th will be given a $0.43 dividend. On a consensus basis, analysts have a one year target price of 124.67.Gilead Sciences, Inc. The stock was sold at an average price of $102.73, for a total transaction of $15,409,500.00. This represents a $1.72 dividend on an annualized basis and a dividend yield of 1.58%.

Gilead Sciences, Inc., is a research biopharmaceutical firm that discovers, develops and commercializes innovative medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company’s HIV products comprise Stribild, Complera/ Tybost, Atripla, Truvada, Viread, Emtriva, Eviplera and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Company’s oncology product. The Company’s products and services include railcars and railcar parts, the leasing, management, and maintenance of railcars, inland barges, highway products, aggregates, storage and distribution containers, structural wind towers, electric utility structures and parts and steel components. Its Respiratory products contain Tamiflu and Cayston. Its other products include Macugen and AmBisome.